

# How do I deliver my search results?

Matt Eberle & Diane Webb, BizInt Solutions

PIUG Annual Meeting 2023 Alexandria, VA

www.bizint.com




Choose Your Own Report Adventure

PIUG Annual Meeting 2023

Alexandria, VA

www.bizint.com



Choose
the best
report
format for
you!

# CHARTS, RECORDS & BEYOND!

If you want a spreadsheet so you can sort and filter... **Go to the next slide** 

Or, if your client wants the report in Excel... **next slide please.** 

If you feel like you can pick any slide as long as it's the next one...

Next slide.

# Spreadsheet (Excel)

Works for tabular presentation (and visualization)

Allows for analysis (filter, sort)

Clients think of it as an analysis tool

Not a good fit for records

Images float(not embedded in cells)


Tabular presentation not flexible


No Subtables


Single link per table cell

	А	В	С	D	E	F	G
Combined: CAS-9 October 2020 PatBase, FAMPAT, GenomeQuest, Innovation							
2		Title	Database	Patent Assignee	Patent Number	Inventor(s)	Abstract
3	1 Link	RNA-guided transcriptional regulation	FAMPAT	HARVARD COLLEGE	US 9267135 B2	CHURCH GEORGE M MALI PRASHANT G ESVELT KEVIN M	(US9267135) Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or [CONT.]
4	2 Link	Compositions and methods for targeted gene disruption in prokaryotes	FAMPAT	ZYMERGEN	WO 201570193 A1	LIU OLIVER KIM JEFFREY	(WO2015/070193) The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.
5	3 Link	RNA-Guided Transcriptional Regulation	GQPAT Gold+ Proteins	HARVARD COLLEGE; President and Fellows of Harvard College	US 20140356959	Church George M. MALI Prashant G. Esvelt Kevin M.	Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or more RNAs, introducing into the cell a third foreign nucleic acid encoding a transcriptional regulator protein or domain, [CONT.]

		Title		Patent Number	Patent Assign	nee Inventor(s	s) Abstra	ct			
1		introducing into the nucleic acid encode sequences comple	ne cell a first foreign ing guide RNA ementary to DNA, and ne cell a second foreign ing a Cas9 protein	US 20150140664 A1	BYRNE S M CHURCH G N	CHURCH,	George M. into the RNA so the tar nucleinguided	tion of a target nucleic acid in e cell a first foreign nucleic ac equences complementary to E get nucleic acid, introducing in a acid encoding a Cas9 protein I by the one or more guide RN Il a third foreign nucleic acid e	id encoding one or r NA, where the DNA nto the cell a second that binds to the DI A sequences, introd	more guide . includes I foreign NA and is lucing into	J K L
		1	CAS-9 October 202		tabase	Patent Assignee	Patent Number	Patent Family	Inventor(s)	Abstract	
2		Compositions a gene disruption	1 Link RNA-guided transcr	iptional regulation FAP	MPAT	HARVARD COLLEGE	US 9267135 B2	(Patent : Kind : Date) US 9267133 : B2 : 2016-02-23 US 20140356959 : A1 : 2014-12-04 US 10640789 : B2 : 2020-05-05 US 20160237456 : A1 : 2016-08-18 US 10767194 : B2 : 2020-09-08 US 20200024618 : A1 : 2020-01-23 US 20140356956 : A1 : 2014-12-04 US 20200299732 : A1 : 2020-09-24	CHURCH GEORGE M MALI PRASHANT G ESVELT KEVIN M	(US9267135) Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or [CONT.]	
3 Lin	Link	RNA-guided tra	2 Link Compositions and r gene disruption in p		МРАТ	ZYMERGEN	WO 201570193 A1	WO 201570193 : Ahttps://ppubs.usptc US 20150132263 : external.html?q=(9 US 20150353901 : select this cell.	267135) nn - Click	(WO2015/070193) The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.	
4		COMPOSITION: TARGETED GEN PROKARYOTES	3 Link RNA-Guided Transc	riptional Regulation GQ	PAT Gold+ Proteins	HARVARD COLLEGE; Presid Fellows of Harvard College		US20140356959 :: 20141204 US20140356956 :: US2014356956 :: US2014356959 :: US20160237456 :: US2016237456 :: US20200024618 :: US9267135 ::	Church George M. MALI Prashant G. Esvelt Kevin M.	Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or more RNAs, introducing into the cell a third foreign nucleic acid encoding a transcriptional regulator protein or domain, [CONT.]	
			cell a guide RNA inc transcriptional activ domain as a fusion	ses providing to the DW luding a vator or repressor		HARVARD COLLEGE CHURCH G M ESVELT K M MALI P G	US 20140356959 A	1 US 20140356959 : A1 : 2014-12-04 US 9267135 : B2 : 2016-02-23	CHURCH, George M. MALI, Prashant G. ESVELT, Kevin M.	Modulating expression of a target nucleic acid in a cell comprises providing to the cell a guide RNA complementary to the target nucleic acid sequence including a transcriptional activator or repressor domain as a fusion protein for modulating target nucleic acid expression in vivo; and providing to the cell a nuclease null Cas9 protein that interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner. [CONT.]	
			SCX7AC9 (+)						•		•







## Text Document (Word)

Allows for a mix of presentations - tables and records, text and images

Editable and can be added to an existing document or template

Tabular presentation can be flexible

Subtables

Images in cells and embeddable in the document

Multiple links in a table cell

Not designed for analysis

Interactivity is limited (model is a document/printed publication)

				1	Patent	Kind	Date	Abstract	
RNA repr		1a Pathase   link 1b FAM   link 1c GQP   link 1d GQP   link 1e GQP   link 1f GQP   link 1g GQP   link 1t Innov   link 1t Innov   link	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	CHERCH DZHORDZH M CHURCH GEORGE M ESVELT KEVIN M GEORGE M CHURCH KEVIN M ESVELT KEVIN M IWANICKI MALI PRASHANT G PRASHANT G MALI	US 9267135 US 20140356959 US 10640789 US 20160237456 US 10767194 US 20200024618 US 20140356956 US 20200299732	B2 A1 B2 A1 B2 A1 A1 A1	2016-02-23 2014-12-04 2020-05-05 2016-08-18 2020-09-08 2020-01-23 2014-12-04 2020-09-24	(US9267135) Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or [CONT.]	
	1i <u>Innox</u>		1a Pathase	1a Pathase			1b <b>FAM</b>	1b FAM	W No.
intro acid	ering a target nucleic acid in a cell by roducing into the cell a first foreign nucleic d encoding guide RNA sequences mplementary to DNA, and introducing into	2a Patbase   link 2b FAM   link 2c GQP   link	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	BYRNE SUSAN M CHURCH GEORGE M GEORGE M CHURCH	EP 3071698 EP 3071698 EP 3071698	B1 A2 A4	2019-09-04 2016-09-28 2017-06-28	(EP3071698) Methods of simultaneously excising large nucleic acid sequences from a target	* M. MA
	cell a second foreign nucleic acid	2d GQP   Iii	6b CDDI		6a <b>CortPat</b>			6c Patbase	6c Patbase
ence	encoding a Cas9 protein	2e GQP   /ii				_			
		2g GQP   //ii 2h GQP   //ii 2i GQP   //ii 2j GQP   //ii		m Clarivate Analytics 1b onts from Clarivate		overy I	Intelligence 1	c PatBase	
	2k Innov	V	VO 2018107	7088 A2					
poly DNA mod treat dise	w bacteriophage comprising ynucleotide that expresses RNA-directed A-binding polypeptide and targeting dule comprising guide RNA, used e.g. for ating autoimmune and inflammatory ease, and disease caused by bacterial ection	3b FAM   //ii	etapneumovirus amd pa atent ID Number: 40 ast Change Date: 20 riginal Assignee: Mode	arainfluenza virus infections 88378 20-10-03		ovirus o	r human parai	nfluenza virus 3 F proteins co-formulated	with lipids - useful in treating
		Pa	tent Publications						
	3f Innov.		Patent	Kind Date					
	· · · · · · · · · · · · · · · · · · ·		WO 201810708	88 A2 2018-06-14					
to la constant									

US 20200069794 A1 2020-03-05

Date

Priority Information

Application

OK, but *my* attorneys would like to see the records *their way*.

With selected fields from the records in yellow boxes...

A space for their notes...

And the full claims...

Next slide please.

## "Summary Record" export

Title: Modulating expression of a target nucleic acid comprises providing to the cell a guide

RNA including a transcriptional activator or repressor domain as a fusion protein, and

providing to the cell a nuclease null Cas9 protein

Database: Derwent World Patents Index

Derwent World Patents Index

GQPAT Gold+ Proteins GQPAT Gold+ Proteins

PatBase **FAMPAT** 

Patent Family: Patent Kind Date 2014-12-04 US 2014356959 US 2014356956 2014-12-04 2014-12-11 AU 2014274939 WO 14197568 2014-12-11 2015-03-12 WO 14197568 CA 2914638 2015-12-04 KR 20160014036 2016-02-05

Probable Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Sequence Locations: % Identity Length Seq. ID Number Location US20140356959-0001 100.00 1368 probable disclosure (not found by automated parsing) US20140356956-0001 100.00 probable disclosure (not found by 1368

automated parsing)


Notes - please provide further detail on this...

#### Claims:

1. A method of modulating expression of a target nucleic acid in a cell comprising providing to the cell a guide RNA complementary to the target nucleic acid sequence including a transcriptional activator or repressor domain as a fusion protein for modulating target nucleic acid expression in vivo providing to the cell a nuclease null Cas9 protein that interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner, wherein the guide RNA including the transcriptional activator or repressor domain as a fusion protein and the Cas9 protein co-localize to the target nucleic acid sequence and wherein the transcriptional activator or repressor domain modulates expression of the target nucleic







Yes, but <u>my</u> attorneys care more about the <u>chemical structures</u>.


They want to see each structure once...

In a Word table...

With all the associated references...

Next slide please.

### Summary Record export with Hit Structures



### **Index of Hit Structures**

rle				
E		Substance	Structure	
13	1	1655492-02-6  2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]-		p mab c E pa
Ť			Each hit substance	a tr b c
Ţ	2	1364682-96-1	identified	P P
RN	_	1-Propanol, 3-[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)	OH OH NH2  F CM2 CRN 76-05-1	b d trin
~			OH F	
/			F F	

Structures with annotations

mycobacterial activity of benzoxaborole compds. Reference 1

prepn. and application tricyclic benzoxab compds.

Reference 2

prepn. of benzoxaborole derivs. useful for treating bacterial infections Reference 3

Links to references for each structure


Multiple images (continuation) or mixtures


prepn. of



### Allow styles for summary records







Depending on your search, you could be happy with records that are a mix of summary and detail -- seek no further, happily ever after, here you are.


The End.

Really? You're looking for something more?

More than these records?

Where we're going there are no roads (and not much software).


But there are....slides.







	Drug Name(s)	Database	bookmark link		Enhanced Title		In the Future?		
1 a	mRNA-1653	Cortellis Patents (5) from Clarivate Analytics	<a href="Excel+Word&lt;br&gt;demo.docx#src_5676719!&lt;br&gt;k&lt;/a&gt;&lt;/th&gt;&lt;th&gt;5_1">Lin meta co-fo</a>	cines comprising RNA polynucleotides en apneumovirus or human parainfluenza vio ormulated with lipids - useful in treating me d parainfluenza virus infections.		Excel export with automatically generated links to Summary Records			
1 b	mRNA-1653	Clarivate Drug						arate Wor	d file.
-	1	Combined: R	NA vaccine Cortell	lis+Integrity	y+Patbase				
C	2	Drug Name(s)	bo	ookmark link	Enhanced Title		Probable Assignee		TOWN MANY
	1	mRNA-1653 {1b CDDI}	Liı	nk to record	Vaccines comprising RN encoding human met human parainfluenza	1. Drug Name(s):	MODERNATX INC  mRNA-1653  Cortellis Patents from	Clarivate Analytics	
2 a	SARS-CoV-2 vaccine (im, COVID-19/S/ CureVac				formulated with lipid: metapneumovirus an infections. {1a CortPat}	Enhanced Title:	Clarivate Drug Discove PatBase Vaccines comprising F parainfluenza virus 3 F	ery Intelligence  RNA polynucleotides  proteins co-formula	encoding human metapneumovirus or human
2 b	R-6717	R-6717 {2b CDDI}	Lin		C:\Users\willmore\AppData\Lc Excel+Word demo.docx -	Probable Assignee:	metapneumovirus amo MODERNATX INC		infections.
2 c	4	(25 CDDI)		src_567	767195_1 - Click once to folk and hold to select this cell. The nucleoprotein or cass treating Lassa virus in {2a CortPat}	Patent Family:	Patent WO 2018107088 WO 2018107088 EP 3551193 EP 3551193	Kind         Date           A2         2018-06-14           A3         2018-07-12           A2         2019-10-16           A4         2020-08-19	
	3		Lir	nk to record	In vitro-transcribed R		<u>US 2020069794</u> HK 40016413	A 2020-03-05 A1 2020-09-11	
		{3b CDDI}			encoding an antigen phemagglutinin) and a	Indications: Hyperlinks:	Infection, metapneumo	ovirus (MPV); Infecti	on, parainfluenza virus
					RNA activating RIG-1	Notes	<u>3001CE</u>   WO 20101070	700 AZ   Lattous Latin	y riee
					cancer or pathogenic {3a CortPat}	Claims:			
	5								g the nucleic acid sequence identified by SEQ ID uence at least 95 percent identical to the nucleic

<sup>1.</sup> A vaccine comprising (a) a RNA polynucleotide comprising the nucleic acid sequence identified by SEQ ID NO:4 or a RNA polynucleotide comprising a nucleic acid sequence at least 95 percent identical to the nucleic acid sequence identified by SEQ ID NO:4 encoding a human metapneumovirus (hMPV) F protein, and (b) a RNA polynucleotide comprising the nucleic acid sequence identified by SEQ ID NO:5 or a RNA polynucleotide comprising a nucleic acid sequence at least 95 percent identical to the nucleic acid sequence.







AdCOVID - Altimmune

Learn more at bizint.com/COVID

Source: Adis R&D Insight, Pharmaprojects, Cortellis, GlobalData Created with VantagePoint – Smart Charts Edition (VP-SCE)

# Slideshow/Visualizations (Powerpoint)

Provides a different way to look at your search results

Can allow you to see multiple items at once along with context

Allows for analysis

A single visualization is generally not enough.

Generally leads back to a review of the chart and records

If you decide that picture is worth a 1,000 records, you've reached The End.

But.

Your client was promised visualizations. When they see the visualizations they want to see the records...



### Companies appearing in the mRNA sector

#### Count of patent families

Filtered by Application Date: Dates/Extract Years up to: < 2020 >

< 2020 >

